Daily Supplementation with Bifidobacterium longum KACC91563 Alleviates Allergic Contact Dermatitis in an Animal Model
Authors:
- Van-Ba HoaVHVan-Ba Hoa
- So-Hyun ParkSPSo-Hyun Park
- Do-Hyun HaDHDo-Hyun Ha
- Je-Hee SonJSJe-Hee Son
- Kil-Ho LeeKLKil-Ho Lee
- Won-Seo ParkWPWon-Seo Park
- Ja-Yeon YooJYJa-Yeon Yoo
- In-Seon BaeIBIn-Seon Bae
- Hyoun-Wook KimHKHyoun-Wook Kim
- Han-Byul KangHKHan-Byul Kang
- Sang-Myeong LeeSLSang-Myeong Lee
- Jun-Sang HamJun-Sang Ham
Open Access
Abstract
Allergic contact dermatitis (ACD) is the most common chronic inflammatory skin disease (or immune-mediated disease), causing disruption to our psychological condition and life quality. In this study, the therapeutic properties of probiotic Bifidobacterium longum (B. longum) was investigated by using an ACD-induced animal model. For ACD induction, BALB/c mice ear and dorsal skin were sensitized with 240 µL of 1% (w/v) 2,4-dinitrochlorobenzene (DNCB) twice (3-day intervals). After a week of the first induction, the mice were re-sensitized by painting on their dorsal skin and ear with 0.4% (w/v) DNCB for a further three times (once per week). Before the ACD induction of 2 weeks and throughout the trial period, the BALB/c mice were supplemented daily with 1 mL of 1.0 × 109 CFU or 5.0 × 109 CFU B. longum using an intragastric gavage method. The ACD-induced mice without B. longum supplementation were used as a control. Results show that B. longum supplementation significantly alleviated ACD symptoms (e.g., ear swelling, epidermal damage) and immune response (e.g., reduced immune cell recruitment, serum IgE level, and cytokine production). The therapeutic efficiency of B. longum increased as the supplementation dose increased. Thus, daily supplementation with 5.0 × 109 CFU probiotic B. longum could be an effective method for the prevention and treatment of ACD.Keywords
Funding Information
- National Institute of Animal Science, Rural Development Administration, Republic of Korea
This publication has 60 references indexed in Scilit:
- Modulation of allergic contact dermatitis via gut microbiota modified by diet, vitamins, probiotics, prebiotics, and antibioticsPharmacological Reports, 2023
- Nuclear receptor Nr1d1 alleviates asthma by abating GATA3 gene expression and Th2 cell differentiationCellular and Molecular Life Sciences, 2022
- Immunological Mechanisms in Allergic Contact DermatitisCurrent Treatment Options in Allergy, 2022
- Lifestyle risk factors and all-cause and cause-specific mortality: assessing the influence of reverse causation in a prospective cohort of 457,021 US adultsEuropean Journal of Epidemiology, 2022
- Clostridia in the gut and onset of atopic dermatitis via eosinophilic inflammationAnnals of Allergy, Asthma & Immunology, 2016
- Cytokines and chemokines: At the crossroads of cell signalling and inflammatory diseaseBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2014
- Bacteriocin production by Bifidobacterium spp. A reviewBiotechnology Advances, 2013
- GATA3 in development and cancer differentiation: Cells GATA have it!Journal of Cellular Physiology, 2009
- The mucosal firewalls against commensal intestinal microbesSeminars in Immunopathology, 2009
- Lactobacilluscasei reduces CD8+ T cell‐mediated skin inflammationEuropean Journal of Immunology, 2004